PCSK9 and Hypercholesterolemia: The two worldwide approved monoclonal antibodies against PCSK9 (evolocumab and alirocumab) for hypercholesterolemia could further increase the magnitude of LDL-C lowering by up to 60%, when administrated as add-on to a statin [2, 15–17], accompanied by a reduced risk of cardiovascular events [18–20] and improved the quality of life [21].